Literature DB >> 3536076

Differential turnover of the subunits of ribonucleotide reductase in synchronized leukemia L1210 cells.

E H Rubin, J G Cory.   

Abstract

Ribonucleotide reductase catalyzes the rate-limiting step in the de novo synthesis of 2'-deoxyribonucleoside 5'-triphosphates that is required for DNA replication. The mammalian enzyme consists of two nonidentical protein subunits that are both required for enzyme activity. In leukemia L1210 cells, enriched in G1-phase cells by centrifugal elutriation, it was found that ribonucleotide reductase activity increased as the cells progressed to S-phase. The two subunits making up the holoenzyme did not increase coordinately. The nonheme iron subunit increased much more rapidly than the effector-binding (EB) subunit. The activity of the holoenzyme paralleled the level of the EB subunit, which was limiting. The half-lives of the holoenzyme and its subunits were determined in S-phase cells by treatment with cycloheximide. The half-lives of the holoenzyme and the nonheme iron and EB subunits, as determined by enzyme activity, were 3.5, 7.6, and 4 h, respectively. These half-lives are consistent with the data that indicate that the EB subunit is the limiting component in L1210 cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3536076

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.

Authors:  M Matsumoto; T Tihan; J G Cory
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.

Authors:  G Lassmanm; B Liermann; W Arnold; K Schwabe
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells.

Authors:  Martha Rodriguez Sandoval; Kumudha Balakrishnan; Rajyalakshmi Luthra; Michael Keating; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2013-07-29

4.  MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.

Authors:  Adriana Estrada-Bernal; Moumita Chatterjee; S Jaharul Haque; Linlin Yang; Meredith A Morgan; Shweta Kotian; David Morrell; Arnab Chakravarti; Terence M Williams
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.